Professor Peter C Taylor

Publications


Journals

  • Taylor PC; Patel S; Paleolog E; McCloskey RV; Feldmann M; Manil RN. (1 Sep 1998). Reduced synovial vascularity following TNF alpha blockade in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM. 41:S295-S295. Author weblink.
  • TAYLOR PC. (1 Apr 1992). THE SEVERE COMBINED IMMUNODEFICIENT (SCID) MOUSE - XENOGENEIC-SCID CHIMERAS IN THE INVESTIGATION OF HUMAN AUTOIMMUNE-DISEASE. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY. 73:251-259. Author weblink.
  • Taylor PC. (1 Mar 2006). Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of inflixin ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis (vol 54, pg 47, 2006). ARTHRITIS AND RHEUMATISM. 54:1028-1028. Author weblink DOI.
  • Taylor PC; Maini RN; Tak PP; Breedveld FC; Smeets TJM; Daha MR; Kluin PM; Meinders AE. (1 Apr 1997). Decrease in cell adhesion molecules by treatment with anti-tumor necrosis factor a monoclonal antibody - Reply. ARTHRITIS AND RHEUMATISM. 40:789-790. Author weblink DOI.
  • Steuer A; Blomley M; Cosgrove D; Maini RN; Taylor PC. (1 Sep 2000). Combined power color Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in rheumatoid arthritis. ARTHRITIS AND RHEUMATISM. 43:S292-S292. Author weblink.
  • Taylor PC; Paleolog EM; Maini RN. (2001). Similar effects of pulse corticosteroid and tumor necrosis factor alpha blockade in rheumatoid arthritis - reply (letter). Arthritis Rheum. 44:245-246.
  • PALEOLOG EM; TAYLOR PC; HUNT M; TAK PP; ELLIOTT MJ; FELDMANN M; BREEDVELD FC; MAINI RN. (1 Sep 1995). TREATMENT OF RHEUMATOID-ARTHRITIS WITH ANTIBODY TO TNF-ALPHA DECREASES EXPRESSION AND SHEDDING OF E-SELECTIN. ARTHRITIS AND RHEUMATISM. 38:757-757. Author weblink.
  • Maini RN; Taylor PC; Szechinski J; Pavelka K; Broll J; Balint G; Emery P; Raemen F; et alPetersen J; Smolen J; Thomson D; Kishimoto T. (1 Mar 2008). Double-blind randomized controlled clinical-trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate (vol 54, pg 2817, 2006). ARTHRITIS AND RHEUMATISM. 58:887-887. Author weblink DOI.
  • Steuer A; Taylor PC; Blomley MJ; Maini R; Cosgrove DO. (1 Nov 2001). High frequency power Doppler ultrasound reveals hypervascular erosions are common in early rheumatoid arthritis. RADIOLOGY. 221:506-506. Author weblink.
  • Ulfgren AK; Anderssson U; Engstrom M; Klareskog L; Maini RN; Taylor PC. (1 Sep 1999). Systemic anti-TNF alpha therapy in rheumatoid arthritis (RA) down-regulates synovial TNF alpha synthesis. ARTHRITIS AND RHEUMATISM. 42:S94-S94. Author weblink.
  • Taylor PC; Miotla JM; Etherington P; Winlove P; Young S; Paleolog E; Maini RN. (1 Sep 2000). VEGF release is associated with hypoxia in inflammatory arthritis(.). ARTHRITIS AND RHEUMATISM. 43:S296-S296. Author weblink.
  • Taylor PC; Steuer A; Charles P; Gruber J; Cosgrove DO; Blomley MJK; Wagner C; Marsters P; et alDeWoody K; Maini RN. (1 Sep 2001). Early RA patients on infiliximab therapy show significant changes in sonographic measures of joint vascularity and serum VEGF by 18 weeks. ARTHRITIS AND RHEUMATISM. 44:S152-S152. Author weblink.
  • Ballara SC; Paleolog EM; Taylor PC; Feldmann M; Maini RN. (1 Sep 1999). Elevated serum vascular endothelial growth factor in early arthritis. ARTHRITIS AND RHEUMATISM. 42:S244-S244. Author weblink.
  • PLATERZYBERK C; CARAPETI M; TAYLOR PC; MAINI RN. (1 Jan 1992). CD5+B CELLS - POSSIBLE TARGET FOR THE ACTION OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID-ARTHRITIS. BRITISH JOURNAL OF RHEUMATOLOGY. 31:191-191. Author weblink.
  • TAK PP; TAYLOR PC; BREEDVELD FC; MACFARLANE JD; SMEETS TJM; DAHA MR; KLUIN PM; MEINDERS AE; et alMAINI RN. (1 Sep 1995). INFILTRATE ANALYSIS OF RHEUMATOID SYNOVIAL TISSUE BEFORE AND AFTER ANTI-TNF-ALPHA MONOCLONAL-ANTIBODY TREATMENT. ARTHRITIS AND RHEUMATISM. 38:196-196. Author weblink.
  • TAYLOR PC; WILLIAMS DG; MAINI RN. (1 Jan 1992). SEROLOGICAL AND PATHOLOGICAL FEATURES OF RHEUMATOID-ARTHRITIS TRANSFERRED TO SEVERE COMBINED IMMUNODEFICIENT (SCID) MICE. BRITISH JOURNAL OF RHEUMATOLOGY. 31:6-6. Author weblink.
  • Puntmann VO; Taylor PC; Mayr M. (2011). Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging - a mini-review. Gerontology. 57:295-303. DOI.
  • Taylor PC. (Jan 2007). Rituximab in the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 3:17-26. DOI.
  • Taylor PC. (Jun 2010). Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Curr Opin Pharmacol. 10:308-315. DOI.
  • Puntmann VO; Taylor PC; Barr A; Schnackenburg B; Jahnke C; Paetsch I. (Mar 2010). Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. Rheumatology (Oxford). 49:528-535. DOI.
  • Taylor PC; Feldmann M. (1 Oct 2009). Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. NATURE REVIEWS RHEUMATOLOGY. 5:578-582. Author weblink DOI.
  • Kiely PD; Brown AK; Edwards CJ; O'Reilly DT; Ostör AJ; Quinn M; Taggart A; Taylor PC; et alWakefield RJ; Conaghan PG. (Jul 2009). Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford). 48:765-772. DOI.
  • Taylor PC. (Mar 2009). How do the efficacy and safety of abatacept and infliximab compare in the treatment of active RA?. Nat Clin Pract Rheumatol. 5:126-127. DOI.
  • Taylor PC. (1 Oct 2008). MRI-detected bone marrow edema in early rheumatoid arthritis. NATURE CLINICAL PRACTICE RHEUMATOLOGY. 4:516-517. Author weblink DOI.
  • Fisher BA; Dolan K; Hastings L; McClinton C; Taylor PC. (Nov 2008). Prevalence of subjective voice impairment in rheumatoid arthritis. Clin Rheumatol. 27:1441-1443. DOI.
  • Sivakumar B; Akhavani MA; Winlove CP; Taylor PC; Paleolog EM; Kang N. (Jan 2008). Synovial hypoxia as a cause of tendon rupture in rheumatoid arthritis. J Hand Surg Am. 33:49-58. DOI.
  • Fisher BAC; Frank JW; Taylor PC. (1 Jun 2007). Do Tc-99m-diphosphonate bone scans have any place in the investigation of polyarthralgia?. RHEUMATOLOGY. 46:1036-1037. Author weblink DOI.
  • Taylor PC; Maini RN. (2002). Biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis.
  • Taylor PC; Paleolog EM; Maini RN. (2001). Similar effects of pulse corticosteroid and tumor necrosis factor alpha blockade in rheumatoid arthritis - reply (letter). Arthritis Rheum. 44:245-246.
  • Fisher BA; Taylor PC. (Feb 2007). Etanercept plus sulfasalazine: added value in rheumatoid arthritis?. Nat Clin Pract Rheumatol. 3:70-71. DOI.
  • Maini RN; Taylor PC; Szechinski J; Pavelka K; Bröll J; Balint G; Emery P; Raemen F; et alPetersen J; Smolen J; Thomson D; Kishimoto T; CHARISMA Study Group. (Sep 2006). Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54:2817-2829. DOI.
  • Evans BJ; McDowall A; Taylor PC; Hogg N; Haskard DO; Landis RC. (1 May 2006). Shedding of lymphocyte function-associated antigen-1 (LFA-1) in a human inflammatory response. Blood. 107:3593-3599. DOI.
  • Taylor PC. (Mar 2006). Is abatacept an effective treatment for patients with RA who do not respond to other anti-TNF treatments?. Nat Clin Pract Rheumatol. 2:128-129. DOI.
  • Taylor PC; Steuer A; Gruber J; McClinton C; Cosgrove DO; Blomley MJ; Marsters PA; Wagner CL; et alMaini RN. (Jan 2006). Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis Rheum. 54:47-53. DOI.
  • Taylor PC. (Jun 2005). Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy. Rheumatology (Oxford). 44:721-728. DOI.
  • Taylor PC; Sivakumar B. (May 2005). Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol. 17:293-298.
  • Feldmann M; Brennan FM; Foxwell BMJ; Taylor PC; Williams RO; Maini RN. (1 Jan 2005). Anti-TNF therapy: Where have we got to in 2005?. JOURNAL OF AUTOIMMUNITY. 25:26-28. Author weblink DOI.
  • Taylor PC; Williams RO; Feldmann M. (Dec 2004). Tumour necrosis factor alpha as a therapeutic target for immune-mediated inflammatory diseases. Curr Opin Biotechnol. 15:557-563. DOI.
  • Taylor PC; Feldmann M. (Aug 2004). New approaches to therapeutic immunomodulation for immune-mediated inflammatory disorders. Curr Opin Pharmacol. 4:368-371. DOI.
  • Taylor PC; Steuer A; Gruber J; Cosgrove DO; Blomley MJ; Marsters PA; Wagner CL; McClinton C; et alMaini RN. (Apr 2004). Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 50:1107-1116. DOI.
  • Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN. (2004). Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?. Novartis Found Symp. 256:53-69.
  • Taylor PC. (Jun 2003). Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol. 3:323-328.
  • Taylor PC. (2003). Anti-cytokines and cytokines in the treatment of rheumatoid arthritis. Curr Pharm Des. 9:1095-1106.
  • Taylor PC. (Jan 2003). Anti-TNFalpha therapy for rheumatoid arthritis: an update. Intern Med. 42:15-20.
  • Taylor PC. (2003). The value of sensitive imaging modalities in rheumatoid arthritis. Arthritis Res Ther. 5:210-213. DOI.
  • Andreakos E; Taylor PC; Feldmann M. (Dec 2002). Monoclonal antibodies in immune and inflammatory diseases. Curr Opin Biotechnol. 13:615-620.
  • Etherington PJ; Winlove P; Taylor P; Paleolog E; Miotla JM. (Nov 2002). VEGF release is associated with reduced oxygen tensions in experimental inflammatory arthritis. Clin Exp Rheumatol. 20:799-805.
  • Taylor PC. (Oct 2001). Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol. 19:153-168. DOI.
  • Taylor PC; Williams RO; Maini RN. (Oct 2001). Immunotherapy for rheumatoid arthritis. Curr Opin Immunol. 13:611-616.
  • Ballara S; Taylor PC; Reusch P; Marmé D; Feldmann M; Maini RN; Paleolog EM. (Sep 2001). Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 44:2055-2064. DOI.
  • Taylor PC. (May 2001). Anti-tumor necrosis factor therapies. Curr Opin Rheumatol. 13:164-169.
  • Feldmann M; Maini RN; Bondeson J; Taylor P; Foxwell BM; Brennan FM. (2001). Cytokine blockade in rheumatoid arthritis. Adv Exp Med Biol. 490:119-127.
  • Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M. (Dec 2000). Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. Nihon Rinsho Meneki Gakkai Kaishi. 23:487-489.
  • Ulfgren AK; Andersson U; Engström M; Klareskog L; Maini RN; Taylor PC. (Nov 2000). Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum. 43:2391-2396. DOI.
  • Marinova-Mutafchieva L; Taylor P; Funa K; Maini RN; Zvaifler NJ. (Sep 2000). Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum. 43:2046-2055. DOI.
  • Marinova-Mutafchieva L; Williams RO; Mauri C; Mason LJ; Walmsley MJ; Taylor PC; Feldmann M; Maini RN. (Mar 2000). A comparative study into the mechanisms of action of anti-tumor necrosis factor alpha, anti-CD4, and combined anti-tumor necrosis factor alpha/anti-CD4 treatment in early collagen-induced arthritis. Arthritis Rheum. 43:638-644. DOI.
  • Maini RN; Taylor PC. (2000). Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 51:207-229. DOI.
  • Taylor PC; Williams RO; Maini RN. (2000). Anti-TNF alpha therapy in rheumatoid arthritis--current and future directions. Curr Dir Autoimmun. 2:83-102.
  • Taylor PC; Peters AM; Paleolog E; Chapman PT; Elliott MJ; McCloskey R; Feldmann M; Maini RN. (Jan 2000). Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum. 43:38-47. DOI.
  • Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M. (Nov 1999). Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis. Ann Rheum Dis. 58 Suppl 1:I56-I60.
  • Taylor PC; Peters AM; Glass DM; Maini RN. (Jul 1999). Effects of treatment of rheumatoid arthritis patients with an antibody against tumour necrosis factor alpha on reticuloendothelial and intrapulmonary granulocyte traffic. Clin Sci (Lond). 97:85-89.
  • Griffiths DJ; Cooke SP; Hervé C; Rigby SP; Mallon E; Hajeer A; Lock M; Emery V; et alTaylor P; Pantelidis P; Bunker CB; du Bois R; Weiss RA; Venables PJ. (Mar 1999). Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. Arthritis Rheum. 42:448-454. DOI.
  • Feldman M; Taylor P; Paleolog E; Brennan FM; Maini RN. (Dec 1998). Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases. Transplant Proc. 30:4126-4127.
  • Burnett AK; Clough V; Grundy M; Holme C; Lachmann PK; Marshall C; Scott L; Skacel P; et alSinclair CJ; Taylor PC; Walsh P. (1 Jun 1998). Royal College of Physicians of Edinburgh Consensus Conference on Platelet Transfusion. TRANSFUSION MEDICINE. 8:149-151. Author weblink.
  • Taylor PJ; Jones CE; Martin PT; Lynch SV; Johnson AG; Pond SM. (13 Feb 1998). Microscale high-performance liquid chromatography-electrospray tandem mass spectrometry assay for cyclosporin A in blood. J Chromatogr B Biomed Sci Appl. 705:289-294.
  • Feldmann M; Charles P; Taylor P; Maini RN. (1998). Biological insights from clinical trials with anti-TNF therapy. Springer Semin Immunopathol. 20:211-228.
  • Feldmann M; Brennan F; Paleolog E; Taylor P; Maini RN. (Sep 1997). Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action. Eur Cytokine Netw. 8:297-300.
  • Williams DG; Taylor PC. (5 Apr 1997). Length diversity of immunoglobulin heavy-chain variable regions from rheumatoid arthritis synovium. Ann N Y Acad Sci. 815:516-519.
  • Williams DG; Taylor PC. (Feb 1997). Clonal analysis of immunoglobulin mRNA in rheumatoid arthritis synovium: characterization of expanded IgG3 populations. Eur J Immunol. 27:476-485. DOI.
  • Tak PP; Taylor PC; Breedveld FC; Smeets TJ; Daha MR; Kluin PM; Meinders AE; Maini RN. (Jul 1996). Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum. 39:1077-1081.
  • Taylor PC; Chu CQ; Plater-Zyberk C; Maini RN. (Jun 1996). Transfer of type II collagen-induced arthritis from DBA/1 to severe combined immunodeficiency mice can be prevented by blockade of Mac-1. Immunology. 88:315-321.
  • Maini RN; Elliott MJ; Brennan FM; Williams RO; Chu CQ; Paleolog E; Charles PJ; Taylor PC; et alFeldmann M. (Apr 1995). Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 144:195-223.
  • Taylor PC; Plater-Zyberk C; Maini RN. (Mar 1995). The role of the B cells in the adoptive transfer of collagen-induced arthritis from DBA/1 (H-2q) to SCID (H-2d) mice. Eur J Immunol. 25:763-769. DOI.
  • Plater-Zyberk C; Taylor PC; Blaylock MG; Maini RN. (Dec 1994). Anti-CD5 therapy decreases severity of established disease in collagen type II-induced arthritis in DBA/1 mice. Clin Exp Immunol. 98:442-447.
  • Taylor PC. (Apr 1992). Current status review: the severe combined immunodeficient (SCID) mouse: xenogeneic-SCID chimeras in the investigation of human autoimmune disease. Int J Exp Pathol. 73:251-259.

Chapters in books

  • Taylor P. Imaging. In The year in rheumatic disorders 2002: special issue: rheumatoid arthritis. 159-177. (2002).
  • Abrahams S; Cope A; Taylor PC. Assessment of disease activity in rheumatoid arthritis. In The year in rheumatic disorders 2003. 103-126. Scott D (ed); Cope A (ed). Clinical Publishing Services, Oxford (2003).

Conferences

  • Maini RN; Taylor PC; Pavelka K; Emery P; Szechinski J; Balint G; Broll J. Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). 67th Annual Scientific Meeting of the American-College-of-Rheumatology/38th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, 23 Oct 2003 - 28 Oct 2003. 48:S652-S652. WILEY-LISS (1 Sep 2003). Author weblink.
  • Taylor PC; Steuer A; McClinton C; Blomley M; Wagner C; Marsters P; Maini RN. Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis. 69th Annual Scientific Meeting of the American-College-of-Rheumatology/40th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals. 52:S347-S348. (Sep 2005).
  • Rastogi A; Krasnosselskaia LV; Hughes E; Durighel G; Saeed N; Angwin JS; Binks MH; Newell N; et alTaylor PC; Hajnal JV. Magnetic resonance imaging (MRI) of arthritic wrists - Getting around the pain barrier towards successful longitudinal imaging. Annual Meeting of the British-Society-Rheumatology/Spring Meeting of British Health Professional in Rheumatology. 47:II110-II110. (Apr 2008).
  • Pastor IR; Dickson MC; Binks MH; Lukey PT; Petavy F; McClinton C; Larche M; Taylor PC. B-LYMPHOCYTE chemoattractant (BLC/CXCL13): A potential novel disease activity marker of rheumatoid arthritis. Annual European Congress of Rheumatology (EULAR 2007). 66:452-452. (Jul 2007).
  • Taylor PC. Imaging early abnormalities: A surrogate marker?. Annual European Congress of Rheumatology (EULAR 2007). 66:47-47. (Jul 2007).
  • Larche MJ; McClinton C; Dolan K; Lukey PT; Binks M; Petavy F; Taylor PC. Between-group differences in ultrasonographic measures of synovitis and kinetics of response to oral steroids in active RA. Annual European Congress of Rheumatology (EULAR 2006). 65:587-587. (Jul 2006).
  • Taylor PC; Steuer A; Gruber J; McClinton C; Wagner C; Marsters P; Maini RN. Association between radiographic progression and persistent vascular signal on power doppler imaging in early rheumatoid arthritis. Annual European Congress of Rheumatology (EULAR 2006). 65:505-505. (Jul 2006).
  • Taylor PC; Steuer A; Gruber J; McClinton C; Cosgrove D; Blomley M; Wagner C; Marsters R; et alMaini RN. Ultrasonographic and radiographic evidence of attenuated joint destruction in early RA patients treated with infliximab. Annual European Congress of Rheumatology. 62:160-160. (Jul 2003).
  • Taylor PC; Steuer A; McClinton C; Douglas J; Wagner C; Marsters P; Maini RN. Comparison of remission induction in erosive early KA assessed by DAS28 calculated using either ESR or CRP in infliximab plus MTX combination therapy or MTX monotherapy. Annual European Congress of Rheumatology. 64:417-418. (Jul 2005).
  • Taylor PC; Steuer A; Gruber J; McClinton C; Blomley M; Wagner C; Marsters R; Maini RN. Kinetics of change in erosion scores as assessed by plain radiography and high frequency ultrasound in a randomised, controlled trial of infliximab plus MTX versus MTX only therapy in erosive early rheumatoid arthritis. Annual European Congress of Rheumatology. 64:89-89. (Jul 2005).
  • Roengpithya C; Patterson DA; Taylor PC; Livingston AG. Development of stable organic solvent nanofiltration membranes for membrane enhanced dynamic kinetic resolution. Conference of the European-Membrane-Society (EUROMEMBRANE 2006). 199:195-197. (20 Nov 2006).
  • Sivakumar B; Akhavani M; Kang N; Taylor PC; Paleolog E. Hypoxia-driven angiogenesis is a key feature of tendon disease in rheumatoid arthritis. BSR Annual Meeting/BHPR Spring Meeting. 45:I39-I40. (Apr 2006).
  • Gibbins E; Irwin JL; Livingston AG; Muir JC; Patterson DA; Roengpithya C; Taylor PC. Dynamic kinetic resolution of racemates using membrane-separated catalysts. 229th National Meeting of the American-Chemical-Society, 13 Mar 2005 - 17 Mar 2005. 229:U550-U550. AMER CHEMICAL SOC (13 Mar 2005). Author weblink.
  • Donatien P; Sandhu V; Peston D; Sandisson A; Taylor PC. Synovial hypoxia inducible factor-1 alpha expression is inversely related to tissue oxygen levels in vivo in inflammatory arthritis. 25th European Workshop for Rheumatology Research, 24 Feb 2005 - 27 Feb 2005. 7:S6-S6. BIOMED CENTRAL LTD (1 Feb 2005). Author weblink DOI.
  • Taylor PC; Steuer A; Gruber J; McClinton C; Cosgrove D; Blomley M; Wagner CL; Marsters PA; et alMaini RN. Comparison of ultrasonographic measures of synovitis and radiographic assessment of structural damage over two years in a randomised, controlled trial of infliximab therapy in erosive early rheumatoid arthritis. 68th Annual Scientific Meeting of the American-College-of-Rheumatology/39th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, 16 Oct 2004 - 21 Oct 2004. 50:S402-S402. WILEY-LISS (1 Sep 2004). Author weblink.
  • Taylor PC; Steuer A; Gruber J; McClinton C; Cosgrove D; Blomley M; Wagner C; Marsters P; et alMaini R. Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis. 66th Annual Scientific Meeting of the American-College-of-Rheumatology/37th Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals, 24 Oct 2002 - 29 Oct 2002. 46:S334-S334. WILEY-LISS (1 Sep 2002). Author weblink.
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook